The overall mission of this CHAVI-ID application is to define immunogens and immunization regimens that induce sustained HIV cross-protective B cell and CD4+ T cell responses in preclinical models and, thereby, guide product development strategies for a preventive human AIDS vaccine. Focus #1 will concentrate on B cell and antibody research to facilitate the development of immunogens and immunization protocols that elicit protective broadly neutralizing antibody responses. Our overall strategy in this focus can be briefly summarized in the following goals: 1) To fully define a comprehensive map of the broadly neutralizing (bn) epitopes of the HIV Env spike. Breakthroughs in generating broadly neutralizing human monoclonal antibodies (bnMAbs) in the last two years are bringing this goal within reach; 2) To determine which of the HIV bnMAbs provide the most effective protection against viral challenge in the non-human primate (NHP) model. At the same time, we shall closely monitor developments in the field, including suggestions that some non-neutralizing antibodies may have protective qualifies that might be exploited in vaccine discovery; 3) To determine which HIV broadly neutralizing Abs (bnAbs) are most readily elicited through natural infection and how and when they are elicited using several large cohorts to which we have unique access; 4) To determine which immunogens and immunization strategies best stimulate HIV bnAb generation in the knock-in mouse and NHP models, drawing upon data collected on bnAbs in goals 1-3 and emerging from Focus #2. As we gather together information on optimal immunogens and immunization strategies, we will move forward with small-scale human trials with the advice and close involvement of our Vaccine Discovery Scientific Research Support Component.

Public Health Relevance

With 33 million infected individuals worldwide, an HIV vaccine is urgently needed to slow and eventually eliminate new infections. Protection by most licensed vaccines is associated with the induction of neutralizing antibodies. This proposal seeks to discover immunogens and immunization strategies that induce broadly neutralizing antibodies able to protect against exposure to global HIV isolates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
4UM1AI100663-05
Application #
9089825
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
2016-07-01
Project End
2019-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
5
Fiscal Year
2016
Total Cost
$11,301,236
Indirect Cost
$4,352,222
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Martinot, Amanda J; Abbink, Peter; Afacan, Onur et al. (2018) Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys. Cell 173:1111-1122.e10
Lin, Ying-Cing; Pecetta, Simone; Steichen, Jon M et al. (2018) One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice. EMBO J 37:
Stanfield, Robyn L; Haakenson, Jeremy; Deiss, Thaddeus C et al. (2018) The Unusual Genetics and Biochemistry of Bovine Immunoglobulins. Adv Immunol 137:135-164
Andrabi, Raiees; Bhiman, Jinal N; Burton, Dennis R (2018) Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol 53:143-151
Havenar-Daughton, Colin; Sarkar, Anita; Kulp, Daniel W et al. (2018) The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Sci Transl Med 10:
Keeffe, Jennifer R; Van Rompay, Koen K A; Olsen, Priscilla C et al. (2018) A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. Cell Rep 25:1385-1394.e7
Niessl, Julia; Kaufmann, Daniel E (2018) Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development. Viruses 10:
Cao, Liwei; Pauthner, Matthias; Andrabi, Raiees et al. (2018) Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. Nat Commun 9:3693
Crotty, Shane (2018) Do Memory CD4 T Cells Keep Their Cell-Type Programming: Plasticity versus Fate Commitment? Complexities of Interpretation due to the Heterogeneity of Memory CD4 T Cells, Including T Follicular Helper Cells. Cold Spring Harb Perspect Biol 10:
Struwe, Weston B; Chertova, Elena; Allen, Joel D et al. (2018) Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell Rep 24:1958-1966.e5

Showing the most recent 10 out of 336 publications